Company Overview

Dedicated to bringing one product to market
Endovalve is developing and commercializing a mitral valve replacement system for treating mitral regurgitation (MR). The Endovalve system is designed for insertion during a minimally invasive surgical procedure, allowing a complete valve replacement without the risks and complications associated with both sternotomy and cardiopulmonary bypass.

While some 50,000 patients have either valve repair or valve replacement surgery each year, the majority of an estimated four million MR sufferers in the United States let the disease go untreated in part because of the fear and risks associated with cardiopulmonary bypass. While there are a variety of new mitral valve repair techniques being developed, Endovalve is focused on developing a replacement system that can be delivered via minimally invasive surgery, with the potential for simpler insertion and markedly greater reduction or elimination of mitral regurgitation when compared with minimally invasive repair techniques. We believe that this type of replacement system and procedure could offer a more cost-effective and safer alternative to current treatments, and a vastly superior alternative to doing nothing, especially in patients who today do not get offered surgery because of pre-existing illness.